Screening biomarkers for autism spectrum disorder using plasma proteomics combined with machine learning methods

Xiaoxiao Tang1, Xiaoqian Ran1, Zhiyuan Liang1

  • 1College of Life Science and Oceanography, Shenzhen University, Shenzhen 518071, PR China.

Insights

This study identified four plasma proteins (PPBP, APCS, FGG, PF4V1) as potential blood biomarkers for early autism spectrum disorder (ASD) detection. These biomarkers show promise for improving early diagnosis and intervention strategies in children.

Area of Science:

  • Biochemistry
  • Proteomics
  • Neurodevelopmental Disorders

Background:

  • Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder in children.
  • Early intervention significantly improves outcomes for individuals with ASD.
  • Identifying reliable biomarkers is crucial for early ASD detection and timely intervention.

Purpose of the Study:

  • To investigate novel blood-based protein biomarkers for the early detection of autism spectrum disorder (ASD).
  • To identify and validate a panel of proteins in plasma that can differentiate ASD cases from controls.

Main Methods:

  • Utilized Sequential Window Acquisition of All Theoretical Spectra-Mass Spectrometry (SWATH-MS) for initial proteomic profiling.
  • Employed machine learning algorithms to screen for candidate biomarkers from differentially expressed proteins.
  • Validated potential biomarkers using targeted proteomics Multiple Reaction Monitoring (MRM) in an independent cohort.

Main Results:

  • Identified 51 differentially expressed proteins (DEPs) associated with immune response and metabolic pathways.
  • Machine learning identified 10 candidate protein biomarkers.
  • Four proteins (PPBP, APCS, FGG, PF4V1) were validated as significant discriminators, achieving an Area Under the Curve (AUC) of 0.8087 for ASD screening.

Conclusions:

  • A specific combination of four plasma proteins demonstrates significant potential as a screening tool for autism spectrum disorder (ASD).
  • These findings support the development of blood-based assays for early ASD identification.
  • Further research is warranted to confirm the clinical utility of these protein biomarkers in diverse populations.
Abstract